Skip to main content
Premium Trial:

Request an Annual Quote

Oxford GlycoSciences and Incyte Launch Proteomics Drug Discovery Program

Premium

BOSTON--Incyte Pharmaceuticals of Palo Alto, Calif., and Oxford GlycoSciences of Oxford, UK, jointly launched the LifeProgram protein expression product last month at the IBC Drug Discovery Technology Conference here. LifeProgram facilitates the identification and validation of new drug targets, therapeutic proteins, and human disease markers. This new program provides an extensive proteomics database, software to analyze and visualize proteomics data, and access to optional customer-directed services at Oxford to develop custom protein expression data.

LifeProgram's dataset was generated from a variety of human tissues and cell cultures, selected to represent relevant therapeutic areas, such as cancer, the cardiovascular system, immunology, metabolic disease, and the central nervous system. Incyte and Oxford developed all of the data from hundreds of Oxford Pem protein expression maps, which are composed of two-dimensional gel electrophoresis images that display a range of proteins expressed in a tissue sample.

Filed under

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.